Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRecce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.33 AUD 0.00(0%)
Last update at 2026-11-09T02:00:00Z
VOLUME
12509
Market Cap
100.93M

Momentum Score

…

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.33
High
52 Week Price Range
0.27
Low
0.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Recce Pharmaceuticals is a clinical-stage Australian biotechnology company developing broad-spectrum synthetic anti-infective candidates using its RECCE platform to address bacterial, fungal and viral infections. Long-term growth may benefit from rising global demand for novel antimicrobials to counter resistance, progress through clinical development, and potential licensing or commercialization partnerships that could support market access if regulators approve products.

Principal risks include high clinical and regulatory uncertainty, ongoing financing requirements to fund development and scaling, and execution challenges competing against established antibiotic developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.33
Dividend Yield
-
Revenue TTM
9.47M
Revenue Per Share
0.03
Gross Profit TTM
1.24M
Debt / Equity
-0.62
ROE
-1277.63%
Net Debt
7.75M
ROCE
297.18%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -23.84M -21.43M -22.57M -13.08M -10.99M
Net income -14.96M -21.43M -17.66M -13.08M -10.99M
Selling general administrative - 8.46M 5.87M 4.11M 2.37M
Selling and marketing expenses - 1.24M 1.24M 1.12M 0.99M
Gross profit -0.36M -2.94M -2.19M - -
Reconciled depreciation - 0.36M 0.37M 0.22M 0.19M
Ebit -23.16M -20.41M -21.72M -12.90M -10.98M
Ebitda -22.81M -20.33M -21.35M -12.69M -10.80M
Depreciation and amortization 0.36M 0.07M 0.37M 0.22M 0.19M
Operating income -23.16M -22.88M -22.05M -12.90M -10.98M
Other operating expenses 23.16M 30.39M 21.37M 17.24M 12.60M
Interest expense 1.66M 1.26M 0.85M 0.17M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.11M 0.19M 0.18M 0.09M
Net interest income - -1.15M -0.66M -0.12M 0.08M
Income tax expense -8.88M -6.74M -4.91M 4.45M 0.00M
Total revenue - 7.51M 5.03M 4.43M 3.18M
Total operating expenses 22.81M 19.94M 21.68M 17.24M 12.60M
Cost of revenue 0.36M 10.45M 7.22M - -
Total other income expense net -0.68M 1.45M -0.52M 4.28M -0.00M
Net income from continuing ops - -21.43M -17.66M -13.08M -10.99M
Net income applicable to common shares - -21.43M -17.66M -13.08M -10.99M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 8.53M 12.41M 6.37M 2.56M 12.62M
Intangible assets - - - 0.00M 0.00M
Other current assets 0.55M 0.21M 0.56M 0.16M 0.42M
Total liab 25.25M 15.47M 15.89M 5.14M 2.56M
Total stockholder equity -16.72M -3.05M -9.52M -2.59M 10.06M
Other current liab 6.42M - 10.88M 3.90M 1.97M
Common stock 81.73M - 54.84M 44.11M 43.97M
Capital stock - 81.50M 54.84M 44.11M 43.97M
Retained earnings -101.32M -91.50M -70.08M -55.54M -42.46M
Other liab - - - 0.19M 0.12M
Cash 2.69M 10.45M 4.21M 1.56M 11.58M
Total current liabilities 16.32M 6.13M 15.07M 4.85M 2.45M
Current deferred revenue - - - -0.15M -0.07M
Net debt 7.75M - -3.40M -1.31M -11.51M
Short term debt 1.71M - 0.22M 0.15M 0.07M
Short long term debt - 1.53M - - -
Short long term debt total 10.44M - 0.81M 0.25M 0.07M
Other stockholder equity - - - 8.83M -1.51M
Property plant equipment - - - 0.61M 0.44M
Total current assets 7.12M 11.39M 5.14M 1.95M 12.18M
Net tangible assets - - - -2.59M 10.06M
Short term investments - - 0.21M 0.05M 0.02M
Net receivables 3.87M - 0.16M 0.09M 0.18M
Long term debt - 8.60M - - -
Inventory - - - 0.14M -
Accounts payable 8.20M 2.18M 3.97M 0.95M 0.48M
Accumulated other comprehensive income 2.87M - 5.71M 8.83M 8.55M
Non currrent assets other - - 0.00M -0.00M -0.00M
Non current assets total 1.41M 1.03M 1.23M 0.61M 0.44M
Capital lease obligations - 0.64M 0.81M 0.25M 0.07M
Long term debt total - - - 0.10M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.44M -0.14M -0.04M -0.04M
Change to liabilities - - - 0.77M 0.16M
Total cashflows from investing activities 0.12M -0.44M -0.14M -0.04M -0.04M
Net borrowings - 0.59M 5.89M 2.71M -0.14M
Total cash from financing activities 2.01M 26.92M 16.00M 2.71M -0.24M
Change to operating activities - - - -1.01M 1.31M
Net income -14.96M -21.43M -17.66M -13.08M -10.99M
Change in cash -7.75M 6.03M 2.85M -10.02M -9.29M
Begin period cash flow 10.45M 4.42M 1.56M 11.58M 20.87M
End period cash flow 2.69M 10.45M 4.42M 1.56M 11.58M
Total cash from operating activities -9.89M -20.44M -13.01M -12.69M -9.01M
Issuance of capital stock - 28.35M 11.15M 0.10M 0.29M
Depreciation 0.36M - 0.37M 0.22M 0.19M
Other cashflows from investing activities 0.19M -0.18M - - -
Dividends paid - - - - 1.72M
Change to inventory - - - 0.24M -1.47M
Change to account receivables -3.44M 0.28M 0.06M 0.09M 0.06M
Sale purchase of stock - - - 0.10M -1.72M
Other cashflows from financing activities -0.29M -2.02M -1.03M -0.27M -0.39M
Change to netincome - - - 0.33M 0.26M
Capital expenditures 0.06M 0.03M 0.14M 0.04M 0.04M
Change in working capital 3.12M -0.71M 4.27M -0.15M 1.53M
Stock based compensation - - 0.02M 0.33M 0.26M
Other non cash items 1.60M -19.74M 0.39M -0.10M 0.46M
Free cash flow -9.95M -20.47M -13.15M -12.73M -9.05M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RCE
Recce Pharmaceuticals Ltd		 -
-%		 0.33 - - 10.66 183.30 -8.43
CSL
CSL Ltd		 -0.04
0.02%		 202.00 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 0.28
2.08%		 13.96 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 0.66
2.84%		 23.90 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 0.05
2.46%		 2.08 - 454.55 23.43 3.36 -9.86

Profile*

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Governor Macquarie Tower, Sydney, NSW, Australia, 2000

61 2 9000 1907

https://www.recce.com.au

Name Title Year Born
Mr. James Hamilton-Bray Graham GAICD CEO, MD & Exec. Director NA
Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) Chief Scientific Director & Exec. Director NA
Dr. Justin Ward Principal Quality Chemist & Exec. Director NA
Mr. Arthur Kollaras Principal Engineer & Head of Manufacturing NA
Mr. Justin Reynolds Chief Financial Officer NA
Thomas Jarrett Operations Mang. NA
Mr. Daniel Astudillo B.A., B.Com., M.B.A. Head of Marketing NA
Ms. Maggie Niewidok Company Sec. NA
Dr. John K. A. Prendergast Ph.D. Executive Chairman of the Board 1954
Mr. James Hamilton-Bray Graham GAICD CEO, MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…